Home » Stocks » CDNA

CareDx, Inc. (CDNA)

Stock Price: $49.05 USD -2.06 (-4.03%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 2.40B
Revenue (ttm) 169.37M
Net Income (ttm) -19.98M
Shares Out 48.96M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $49.05
Previous Close $51.11
Change ($) -2.06
Change (%) -4.03%
Day's Open 52.64
Day's Range 48.04 - 55.89
Day's Volume 975,047
52-Week Range 13.04 - 55.89

More Stats

Market Cap 2.40B
Enterprise Value 2.20B
Earnings Date (est) Mar 25, 2021
Ex-Dividend Date n/a
Shares Outstanding 48.96M
Float 47.40M
EPS (basic) -0.46
EPS (diluted) -0.44
FCF / Share 0.35
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 0.72%
Payout Ratio n/a
Shares Short 5.23M
Short Ratio 6.88
Short % of Float 11.04%
Beta 0.79
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 139.10
PS Ratio 14.18
PB Ratio 9.51
Revenue 169.37M
Operating Income -25.01M
Net Income -19.98M
Free Cash Flow 17.27M
Net Cash 197.52M
Net Cash / Share 4.03
Gross Margin 54.48%
Operating Margin -14.76%
Profit Margin -11.80%
FCF Margin 10.19%
ROA -7.39%
ROE -10.72%
ROIC -78.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$59.00*
(20.29% upside)
Low
54.0
Current: $49.05
High
66.0
Target: 59.00
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue12776.5748.3240.6328.1427.3122.1020.45
Revenue Growth65.95%58.45%18.93%44.37%3.07%23.57%8.05%-
Gross Profit81.6143.5826.9519.5117.8718.7713.0212.52
Operating Income-24.53-15.58-20.29-37.33-11.930.01-0.86-2.34
Net Income-21.97-46.76-55.47-39.47-13.710.78-3.54-5.06
Shares Outstanding42.1535.6423.3316.5011.865.821.011.01
Earnings Per Share-0.52-1.31-2.38-2.39-1.160.10-3.50-5.01
Operating Cash Flow-2.77-4.01-14.31-16.52-9.75-3.35-0.55-1.78
Capital Expenditures-2.20-2.04-0.19-0.55-1.20-0.73-0.10-0.14
Free Cash Flow-4.97-6.04-14.49-17.07-10.95-4.08-0.64-1.92
Cash & Equivalents38.4864.8126.4717.4030.0436.585.285.98
Total Debt2.37-34.0623.9415.7511.4115.3814.87
Net Cash / Debt36.1164.81-7.59-6.5414.2825.17-10.10-8.89
Assets15213183.5776.7355.6461.149.879.88
Liabilities52.7434.7789.5256.9726.1419.8425.3421.88
Book Value99.0095.93-6.1319.4829.4941.30-151-147
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name CareDx, Inc.
Country United States
Employees 306
CEO Peter K. Maag

Stock Information

Ticker Symbol CDNA
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: CDNA
IPO Date July 17, 2014

Description

CareDx, a precision medicine company, discovers, develops, and commercializes healthcare solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; and AlloMap Heart, a gene expression solution for heart transplant patients. The company also develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and solid organs. In addition, it offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a solution for use in transplantation diagnostic testing. Further, the company provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI and Waitlist Management solutions. It offers its products directly to customers, as well as through third-party distributors. The company has a license agreement with Illumina, Inc. for the development, commercialization, and distribution of next generation sequencing product line for use in transplantation diagnostic testing; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.